3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
5
Genitourinary
2
Breast
2
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
2
Neoplasm Metastasis
1
Interventions
Trastuzumab
9
Paclitaxel
8
Capecitabine
8
trastuzumab deruxtecan
7
Fulvestrant
7
pertuzumab
5
eribulin
5
Gemcitabine
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
Doxorubicin
4
Carboplatin
4
Ado-Trastuzumab Emtansine
4
sacituzumab govitecan
3
ribociclib
3
Vinorelbine
3
Epirubicin
3
Docetaxel
3
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
neratinib
2
larotrectinib
2
exemestane
2
capivasertib
2
abemaciclib
2
Letrozole
2
Fluorouracil
2
Anastrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
olaparib
×
Breast
×
Clear all
NCT02032823
2026-05-06
OlympiA
AstraZeneca
Phase 3
Active not recruiting
1,837 enrolled
20 charts
1 FDA
NCT02000622
2026-02-13
OlympiAD
AstraZeneca
Phase 3
Completed
302 enrolled
26 charts
1 FDA